IDT Biologika opens new manufacturing facility in US

The state-of-the-art facility provides the translational bridge between pre-clinical development and phase II clinical trials with end-to-end capabilities, including process development, cell banking, cGMP manufacturing, purification and formulation, and fill and finish.

IDT Biologika president Ralf Pfirmann said: "The Rockville facility marks a milestone for IDT Biologika as we expand our worldwide operations into the United States and continue our commitment to meet the vaccine development and production needs in key markets.

"With the new facility, we provide U.S. companies with a highly capable and experienced CMO-partner for phase I and phase II clinical vaccine projects right from the heart of the BioMaryland corridor."

The Rockville facility is BSL-2 compliant and meets all U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards. IDT Biologika shares the 75,000-foot building with Aeras, a nonprofit, global biotech organization developing new tuberculosis vaccines for the world, and is partnering with the nonprofit organization on process development and manufacturing of candidate tuberculosis vaccines.

"We’re very pleased that IDT Biologika, a world-class vaccine manufacturer, has chosen Maryland as the location for its first U.S. manufacturing facility," said Ben Wu, Deputy Secretary of the Maryland Department of Business and Economic Development.

"IDT Biologika’s decision to locate here is another example of how international companies are viewing Maryland as a prime location for their cutting-edge research and discoveries that are improving the lives of people across the globe. Our state is home to many vaccine, biotechnology and pharmaceutical companies, to renowned academic institutions, and to government agencies vital to the development of vaccines."